Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group by Parulekar, W.R. et al.
PARULEKAR et al.
CURRENT ONCOLOGY—VOLUME 15, NUMBER 4
179
CANADIAN CENTRE ACTIVITIES
Copyright © 2008 Multimed Inc.
ABSTRACT
The designation “clinically localized prostate cancer”
comprises a group of biologically heterogeneous
tumours with different growth rates and risks of re-
lapse. Because prostate cancer is primarily a disease
of older men, treatment selection must take into ac-
count the prognosis of the tumour, patient age,
comorbidities, side effects of treatment, and patient
preferences. Clinical trials must identify the various
prognostic groups and test the appropriate treatment
strategies within these subgroups.
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1. INTRODUCTION
Prostate cancer is the most common malignancy in
Canadian men and ranks third behind lung and colon
cancer in terms of cancer-related mortality. However,
from 1994 to 2003, mortality from prostate cancer de-
clined at a rate of 2.7% annually. That decline is attrib-
uted both to the widespread use of testing for
prostate-specific antigen (PSA), which has led to a shift
in stage and grade at diagnosis, and to the existence of
effective therapies for clinically localized disease.
In 2007, estimates placed new cases of prostate
cancer at 22,300 and deaths from the disease at 4300 1.
Those statistics highlight some important facts about
prostate cancer:
￿ In most cases, prostate cancer is not a fatal condi-
tion.
￿ Current treatment options still fail to cure or con-
trol disease in a significant proportion of cases,
and approximately 20% of patients die from their
prostate cancer.
Not surprisingly, the treatment strategies under
evaluation in ongoing clinical trials in early prostate
cancer reflect the biologic heterogeneity of the disease.
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They include such diverse therapies as active surveil-
lance for good-prognosis disease and the addition of
cytotoxic chemotherapy to radical radiation or pros-
tatectomy for disease with high risk of relapse. The
present article reviews ongoing studies in localized
prostate cancer conducted by the National Cancer In-
stitute of Canada (NCIC) Clinical Trials Group (CTG).
2. NCIC CTG PR.11: A PHASE III STUDY OF
ACTIVE SURVEILLANCE THERAPY





Tumours detected because of PSA testing comprise
most of the localized prostate cancer cases diagnosed
today. Although testing may allow for diagnosis and
the use of curative therapy at an earlier stage in a po-
tentially life-threatening disease, it also clearly identi-
fies a group of patients with biologically indolent
tumours in whom radical therapy may be unnecessary
and detrimental because of its associated morbidity and
costs 2,3. Previous nonrandomized studies have identi-
fied the prognostic significance of stage and grade in
patients treated with conservative therapy or observa-
tion, thus identifying a patient population for whom
curative therapy can potentially be withheld without
compromise to long-term outcome 4–6. An extension
of the concept of observation is that of “active surveil-
lance,” which entails close follow-up of disease and
intervention with curative intent triggered by early signs
of disease progression.
The strategy of active surveillance for patients with
favourable-risk prostate cancer was evaluated in a large
phase II study by Klotz. Active surveillance was ap-
plied in 331 patients with favourable-risk disease (de-
fined as PSA below 15 ng/mL, Gleason score of 7 or
less, and tumour stage less than T2B), following them
until criteria of early disease progression [defined by
biochemical, histologic (grade), or clinical progression]OPTIMAL TREATMENT STRATEGY IN LOCALIZED PROSTATE CANCER
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were met. Of those patients, 80% had a Gleason score
of 6 or less, and the same proportion had a PSA below
10 ng/mL. With a median follow-up of 72 months, 34%
of patients discontinued active surveillance. Biochemi-
cal progression led to discontinuation in 15%; clinical
progression, in 3%; histologic progression, in 4%; and
patient preference, in 12%. With a median follow-up
of 7 years, overall survival was 85%, and disease-spe-
cific survival was 99%. The median PSA doubling time
for the entire cohort was 7.0 years; a PSA doubling time
of less than 2 years was associated with a high risk of
local progression for patients who underwent radical
prostatectomy. At January 2007, 134 patients remained
on active surveillance 7.
2.2 Study Design
The PR.11 trial is an Intergroup study led by the NCIC
CTG (study chair, Dr. Laurence Klotz) that compares
active surveillance with radical therapy (prostatec-
tomy or radiotherapy depending on physician and pa-
tient choice) at the time of diagnosis in a randomized
phase III setting. Eligible patients are those with a life
expectancy of more than 10 years and favourable-risk
prostate cancer [defined as clinical stage T1B, T1C,
T2A, or T2B at the time of diagnosis; clinical (diag-
nostic biopsy) Gleason score of 6 or less; PSA 10.0
ng/mL or lower]. Patients randomized to the active
surveillance arm will undergo radical intervention
(again, prostatectomy or radiotherapy depending on
physician and patient choice) at the time one or more
of the following pre-specified criteria are met:
￿ Biochemical progression—PSA doubling time less
than 3 years, based on at least 5 separate consecu-
tive measurements over a minimum of 12 months
from the date of the baseline measurement or from
the date that the PSA reached a value greater than
or equal to the PSA before initiation of androgen
deprivation therapy (if applicable), as assessed by
the local investigator.
￿ Histologic or grade progression—Gleason pattern
predominant 4 or greater (that is, a Gleason score
of 7 (4+3) or higher) in re-biopsy of the prostate.
￿ Clinical progression—”local progression” defined
as local progression of prostate cancer resulting
in urinary retention, gross hematuria, or hydro-
nephrosis; or “distant metastasis” defined by ra-
diology, cytology, or histology (or a combination)
at sites remote from the prostate and regional
lymph nodes.
Using a non-inferiority design to rule out a greater
than 5% difference in 15-year survival between the
radical treatment and active surveillance groups, 2130
patients will be accrued over a 5-year period. The pri-
mary endpoint is disease-specific survival. That endpoint,
rather than overall survival, was selected because of the
need to determine the effect of the active surveillance
strategy specifically on prostate cancer mortality. Sec-
ondary endpoints include overall survival, quality of
life, distant disease-free survival, PSA relapse or pro-
gression after radical intervention, initiation of andro-
gen deprivation therapy, proportion of patients on the
active surveillance arm receiving radical intervention,
prognostic significance of PSA doubling time before
diagnosis, and prognostic significance of molecular
biomarkers. Quality of life is an important part of the
study, and the Expanded Prostate Cancer Index, RAND
SF-12, and State–Trait Anxiety Inventory will be used
to provide a comprehensive examination of the vari-
ous components of patient-reported outcomes on study.
The feasibility phase has commenced in designated
centres of participating cooperative groups. If the re-
sults of the feasibility phase indicate sufficient patient
and physician willingness to participate in the random-
ization process, then accrual will be opened widely.




ANDROGEN SUPPRESSION ALONE PLUS
RADIATION THERAPY FOR HIGH-RISK
LOCALIZED ADENOCARCINOMA OF THE
PROSTATE (DART)
3.1 Background
Radical radiotherapy and long-term androgen suppres-
sion constitute an accepted treatment option for local-
ized but high-risk disease as defined by clinical stage
(T3) and high Gleason score (8 or higher) or high PSA
(20 ng/mL or more), or both. Results from previously
conducted randomized studies are consistent with 5-
year disease-free survival rates of 46%–74% with com-
bined therapy 8–10, thus providing the rationale for
continued evaluation of therapies to improve outcome
by control of micrometastatic disease.
Docetaxel is a good candidate drug. The mecha-
nism of action of this agent involves disruption of the
microtubular network critical for mitotic and inter-
phase cellular functions. Doses of 75–100 mg/m2 in-
travenously (IV) administered are well tolerated, with
neutropenia, alopecia, cutaneous reactions, gastro-in-
testinal effects (nausea, diarrhea), neurotoxicity, and
edema being among the most frequently reported ad-
verse events. Severe hypersensitivity reactions char-
acterized by respiratory or circulatory instability or
generalized rash or erythema occur in fewer that 5%
of patients, although lesser grades are more common
11. Using overall survival as the primary endpoint,
two pivotal studies have demonstrated the efficacy of
docetaxel in advanced hormone-refractory prostate
cancer 12,13. Efficacy and adverse event data support
the use of the every-three-weeks docetaxel schedule,
and that schedule has been widely adopted for use in
this patient population.PARULEKAR et al.
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Using changes in PSA as a marker of antitumour
effect, studies have shown that docetaxel is also ac-
tive against hormone-sensitive prostate cancer 14–17.
Furthermore, based on preclinical data that suggest that
docetaxel may result in phosphorylation and inactiva-
tion of the anti-apoptotic protein Bcl-2 (which is
upregulated with androgen suppression), combination
therapy with docetaxel and androgen suppression may
lead to greater antitumour effect 18–21.
Timing of therapy appears to be important. Eigl et
al. implanted LNCaP human prostate cancer and
Shionogi mouse mammary carcinoma cell lines into
mice, and followed up with treatment using one of these
three regimens: castration with paclitaxel on progres-
sion, paclitaxel with castration on progression, or con-
current castration and paclitaxel 22. As compared with
sequential castration followed by paclitaxel, concur-
rent therapy resulted in significantly longer time-to-
progression and time-to-sacrifice in the mice. Notably,
a marked lack of response to castration in the mice
treated initially with paclitaxel was seen.
Clinical studies in patients with locally advanced
prostate cancer have demonstrated the feasibility and
tolerability of combined therapy with docetaxel and
androgen suppression in the neoadjuvant setting before
prostatectomy 23 or radiotherapy 24. In 54 men with
high-risk prostate cancer, McKenzie et al. used one of
two neoadjuvant treatment schedules before radical
radiotherapy: 6 months of androgen suppression, plus
2 cycles of docetaxel 35 mg/m2 IV weekly for 6 weeks
out of 8; or 5 months of androgen suppression, plus 4
cycles of docetaxel 75mg/m2 IV every 3 weeks. An-
drogen suppression was continued after completion of
radiotherapy for a total duration of 3 years. The pri-
mary endpoint was unacceptable toxicity. Eight patients
(14.8%) developed unacceptable toxicity: 5 in the
weekly docetaxel regimen [grade 3 acute genitouri-
nary radiotherapy-related adverse events (n = 3), grade
3 docetaxel hypersensitivity (n = 1), grade 3 fatigue
lasting more than 2 weeks (n = 1)] and 3 in the every-
three-weeks arm [febrile neutropenia (n = 1), grade 4
neutropenia lasting more than 7 days, grade 3 acute
genitourinary radiotherapy-related adverse event (n =
1)]. Compliance with the radiotherapy was excellent,
and all patients completed planned treatment. Long-
term follow-up continues. The neoadjuvant regimen
containing androgen suppression and every-three-weeks
docetaxel was chosen for further study based on the
promising results of this pilot and the proven efficacy
and tolerability of every-three-weeks docetaxel dosing
in the advanced-disease setting.
3.2 Study Design
The NCIC CTG PR.12 trial is a phase III study compar-
ing the every-three-weeks docetaxel and neoadjuvant
androgen suppression regimen piloted by McKenzie
et al. to androgen suppression alone in addition to radi-
cal radiotherapy (three-dimensional conformal
radiotherapy, 46 Gy in 23 fractions, with 24–28 Gy in
12–14 fractions). Study chairs are Drs. Michael
McKenzie and Kim Chi. In both treatment arms, an-
drogen suppression will be given for a total duration of
3 years. Patients with high-risk disease (defined as at
least clinical stage T3 or T4, Gleason score of 8 or
higher, or PSA above 20 ng/mL) are eligible for the
study. The primary endpoint is disease-free survival.
The sample size for this study is estimated based on
detecting an estimated 33.3% risk reduction in disease
progression favouring the experimental arm [hazard
ratio (HR): 0.667], using a 1-sided log-rank test at the
2.5% significance level and 90% power. An estimated
530 patients (assuming a 14.8% loss to follow-up) will
be accrued over 4.5 years, with an additional 5 years
of follow-up. Secondary endpoints include overall sur-
vival, time to biochemical disease progression, time
to local disease progression, time to distant disease
progression, time to next anticancer therapy, progres-
sion-free survival, degree of PSA suppression before
radiotherapy, quality of life, and adverse events. Cen-
tres will be credentialed by NCIC CTG for delivery of
radiotherapy before randomization of the first patient.
Tumour and biologic specimens will be collected dur-
ing the study to determine the prognostic role of
cytokines and insulin-like growth factor axis markers.
In addition, cytokine levels and changes in levels over
time will be correlated with fatigue (as measured by
the Common Terminology Criteria, version 3.0) and
quality of life.
4. NCIC CTG PR.13: RADIOTHERAPY AND
ANDROGEN DEPRIVATION IN
COMBINATION AFTER LOCAL SURGERY
(RADICALS)
4.1 Background
The PR.13 study represents a collaborative effort be-
tween the Medical Research Council Clinical Trials
Unit (United Kingdom) and the NCIC CTG (Canadian
study chairs: Drs. Charles Catton and Fred Saad). This
large pragmatic study is addressing two fundamental
issues in the postoperative management of patients with
resectable prostate cancer: What is the optimal timing
of radiotherapy in these patients? And what role, if any,
does androgen suppression play in determining out-
come? The relevance of the study to current practice
is underscored by the fact that prostatectomy is a stan-
dard of care in men presenting with operable prostate
cancer. In Ontario alone, the number of radical pros-
tatectomies between 1993–1994 and 2003–2004 rose
by 171% 25.
The role of postoperative radiotherapy has been
addressed in three randomized studies:
￿ In EORTC 22911, 1005 patients with pT3 disease
post radical prostatectomy were randomized to
either observation or adjuvant radiotherapy 26. TheOPTIMAL TREATMENT STRATEGY IN LOCALIZED PROSTATE CANCER
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primary endpoint, local control, was modified to
clinical progression-free survival and later to bio-
chemical progression-free survival. After a me-
dian follow-up of 5 years, biochemical
progression-free survival was significantly im-
proved in the irradiated group [74.0%; 98% confi-
dence interval (CI): 68.7 to 79.3] as compared with
the observation group (52.6%; 98% CI: 46.6 to 58.5;
p < 0.0001). Clinical progression-free survival was
significantly better with adjuvant radiation (HR:
0.61; 98% CI: 0.43 to 0.87; p = 0.0009). No differ-
ence in overall survival was detected. The rate of
5-year grade 3 or higher toxic effects was 2.6% in
the no-further-treatment group and 4.2% in the post-
operative irradiation group (p = 0.0726). The inci-
dence of grade 3 urethral stricture and incontinence
was 1.4% (6 patients) in each group.
￿ A similar design was used in SWOG 8794 (NCIC
CTG PR.2), which randomized 425 men with pT3
disease to observation or to radiotherapy to the pros-
tate bed 27. The primary endpoint was metastasis-
free survival, defined as the time from
randomization to first evidence of metastatic dis-
ease or death from any cause. With a median fol-
low-up of 10.6 years, the metastases-free survival
was not significantly different between the two
arms (HR: 0.75; 95% CI: 0.55 to 1.02; p = 0.06).
Overall survival favoured the adjuvant radiotherapy
arm, but did not reach statistical significance (HR:
0.80; 95% CI: 0.58 to 1.09; p = 0.16). The rate of
biochemical relapse was significantly lower in men
with an undetectable PSA level post prostatectomy
(n = 249) treated with adjuvant radiotherapy (HR:
0.43; 95% CI: 0.31 to 0.58; p < 0.001), as was re-
currence-free survival [defined as survival with-
out evidence of measurable or evaluable disease,
excluding PSA relapse (HR: 0.62; 95% CI: 0.46 to
0.82; p = 0.001)]. Approximately one third of pa-
tients randomized to the observation arm ultimately
received pelvic radiotherapy. Rectal complications
(3.3% vs. 0%, p = 0.02), urethral stricture [17.8%
vs. 9.5%; risk ratio (RR): 1.9; 95% CI: 1.1 to 3.1; p =
0.02), and urinary incontinence (6.5% vs. 2.8%; RR:
2.3; 95% CI: 0.9 to 5.9; p = 0.11) were more fre-
quent in the adjuvant radiotherapy arm.
￿ Results from the ARO 96–02 study were reported
at the 2007 meeting of the American Society of
Clinical Oncology 28. That study randomized pa-
tients with pT3 disease to adjuvant radiotherapy or
a “wait-and-see policy.” Those who failed to
achieve an undetectable PSA level postoperatively
on either arm were given a designation of progres-
sive disease and offered radiotherapy. The primary
endpoint, biochemical control, was significantly
improved in the adjuvant radiotherapy arm (HR:
0.53, p = 0.0015).
Taken together, the results of the foregoing trials
fail to fully inform physicians and patients about the
role of post-prostatectomy radiotherapy in current prac-
tice because of differences in outcome definitions used
in the trials, lack of consistent effect of adjuvant ra-
diotherapy on clinical (non-PSA) endpoints, variable
use of late radiotherapy in patients randomized to the
observation arm, and current use of assays for PSA
testing that are more sensitive than those used during
the studies.
The situation regarding the use of hormone therapy
in this group of patients is even less clear. No random-
ized controlled trials have reported addressing the role
and optimal duration of hormone therapy in men re-
ceiving post-prostatectomy radiotherapy. The uncer-
tainty among clinicians regarding the role of adjuvant
radiotherapy and hormone therapy is reflected in re-
cent surveys of urologists and oncologists, indicating a
wide variation in use of these therapies in the post-
prostatectomy patient population 29,30.
4.1 Study Design
The RADICALS trial is designed to address the issues
of radiotherapy timing (immediate vs. early salvage)
and of hormone therapy duration (none vs. short-term
vs. long-term). The primary endpoint is disease-spe-
cific survival. It is estimated that the radiotherapy tim-
ing randomization will have to recruit 2600 patients
and the hormone-duration randomization, 3500 patients.
Many patients will be in both randomizations. The trial
is planned to address these questions over 12–13 years
with 5.5 years of accrual and 7 years of further follow-
up. Secondary endpoints include freedom from treat-
ment failure, clinical progression-free survival, overall
survival, non-protocol hormone therapy, treatment tox-
icity, and patient-reported outcomes.
The radiotherapy timing randomization involves
immediate radiotherapy to the prostate bed versus a
salvage radiotherapy policy at the time of PSA failure.
The radiotherapy will use standard techniques and dose
fractionation schedules: 66 Gy in 33 fractions over 6.5
weeks or 52.5 Gy in 20 fractions over 4 weeks. The
hormone duration randomization involves no hormone
therapy with radiotherapy, compared with short-term
(6 months) hormone therapy beginning shortly before
radiotherapy, compared with long-term (24 months)
hormone therapy beginning shortly before radiotherapy.
Patients who decide not to enter the three-way ran-
domization will be able to choose randomization be-
tween two of the three arms: 0 as compared with 6
months of hormone therapy if they do not want to be
randomized to a long duration of treatment, or 6 as
compared with 24 months of hormone therapy if they
do not want to be randomized to the no-hormone-
therapy treatment arm.
Key eligibility criteria for the radiotherapy timing
randomization include a postoperative serum PSA be-
low 0.4 ng/mL within 3 months after radical pros-
tatectomy, and uncertainty in the opinion of the
clinician and patient regarding the need for immediatePARULEKAR et al.
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postoperative radiotherapy. For the hormone duration
randomization, patients must be expected to receive
radiotherapy (adjuvant or salvage) and must have a PSA
of 10 ng/mL or more at the time of randomization. In
an 18-month feasibility stage, RADICALS will carefully
assess randomization rates and the trial as a whole.
Continuation of the trial beyond the feasibility stage
will be conditional on satisfactory patient accrual.
5. SUMMARY
Ongoing studies at the NCIC CTG are addressing funda-
mental questions regarding the management of local-
ized prostate cancer.
The randomized phase III Intergroup study PR.11
led by NCIC CTG is asking the single most important
question regarding the management of favourable-risk
prostate cancer: Is active surveillance with a radical
intervention based on signs of disease progression as
good as radical intervention at diagnosis? The results
of this study, whether positive or negative, have the
potential to define the management of low-risk pros-
tate cancer globally and to clarify the role of PSA dou-
bling time in decision-making.
The hypothesis being tested in PR.12 is whether
the addition of docetaxel to standard treatment with
androgen suppression combined with radiotherapy im-
proves outcome in a high-risk prostate cancer popula-
tion. This study builds on preclinical data demonstrating
the interaction between taxanes, androgen suppression,
and development of androgen resistance, and also the
extensive literature demonstrating activity of docetaxel
in prostate cancer.
Finally, PR.13 is a large study that seeks to clarify
the roles of post-prostatectomy radiotherapy timing
(adjuvant vs. relapse) and the optimal duration of hor-
mone therapy (0 months vs. 6 months vs. 24 months)
in patients already treated with prostatectomy.
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